1 Title page

2 A Multi-Polygenic Risk Score Approach Incorporating Physical Activity
3 Genotypes for Predicting Type 2 Diabetes and Associated Comorbidities: A
4 FinnGen Study

MSc Vettenterä Elina[1], PhD Joensuu Laura[1], PhD Waller Katja[1], FinnGen[2], PhD Sillanpää

Elina[1,3]*

[1]Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, FINLAND;
[2]FinnGen Authors detailed in the Supplemental Material; [3]Wellbeing Services County of
Central Finland, Jyväskylä, FINLAND

Correspondence to:

*Elina Sillanpää, elina.sillanpaa@jyu.fi , +358 40 1429 639, Faculty of Sport and Health

Sciences, University of Jyväskylä PO Box 35, FI-40014 Jyväskylä, Finland

Running title: Genetic prediction of type 2 diabetes

Manuscript word count: 3098

ABSTRACT

Aims/hypothesis:

Genetic prediction of type 2 diabetes risk has proven difficult using current methods. Recent studies have shown that genetic variants associated with physical activity behavior are linked to type 2 diabetes incidence. This study investigated how a polygenic risk score (PRS) for type 2 diabetes relates to the incidence of type 2 diabetes and its comorbidities and whether incorporating genetic risk from physical activity-related traits and measured lifestyles improves prediction. We hypothesized that adding physical activity genotypes into prediction models would improve predictive accuracy.

Methods: PRSs were calculated for 279,373 Finns in the FinnGen cohort (average age 62 years, 52% women). Cox proportional hazards models were used with follow-up from birth. In addition, we assessed whether predictive ability (concordance index) improved when PRSs for physical activity, sedentary time, cardiorespiratory fitness, muscle strength, and body mass index were included alongside the type 2 diabetes PRS. Finally, we assessed how smoking and body mass index changed the model's predictive ability.

Results: Each standard deviation unit increase in the type 2 diabetes PRS was associated with an 8% higher risk of developing type 2 diabetes. Among individuals with type 2 diabetes, the PRS was linked to higher risks of comorbidities: 4% higher for nephropathy and retinopathy and 5% for severe cardiovascular disease, but not neuropathy. Physical activity-related PRSs were also independently associated with the risk of type 2 diabetes—lower risk for physical activity (7%), cardiorespiratory fitness (6%), and muscle strength (4%) and higher risk for sedentary time (14%) and body mass index (35%). However, physical activity-related PRSs did not significantly improve the model's concordance index (0.644 before vs. 0.672 after adding all other PRSs). In contrast, including body mass index and smoking status increased predictive ability (c-index 0.744).

Conclusions and applicability: PRSs for type 2 diabetes and physical activity-related phenotypes independently predict the incidence of type 2 diabetes and comorbidities. However, adding physical activity-related scores to the model does not significantly improve prediction beyond the type 2 diabetes score. Notably, the PRS for body mass index was better than the PRS for type 2 diabetes in predicting type 2 diabetes incidence. These findings support the hypothesis that genetic pleiotropy may partially explain associations between type 2 diabetes and physical activity behavior.

Keywords: Diabetic comorbidities, polygenic risk scores, type 2 diabetes

Abbreviations:

CRF   Cardiorespiratory fitness

GWAS   Genome-wide association study

PA   Physical activity

PRS   Polygenic risk score

SB   Sedentary behavior

Summary boxes

What is already known about this subject?

- Genetic factors contribute substantially to the risk of type 2 diabetes, but it is
primarily a multifactorial condition in which modifiable lifestyle factors—including
physical activity—play a critical role in onset and progression.

- Genetic variants related to physical activity behavior have been associated with type 2
diabetes.

- The clinical utility of polygenic risk scores in predicting type 2 diabetes risk remains
limited, as they explain only a small proportion of genetic variance and provide
minimal improvement in risk prediction beyond established clinical risk factors.

What is the key question?

- Can the risk estimates for type 2 diabetes and its comorbidities be improved by
incorporating genetic risk factors associated with physical activity and measured
lifestyle behaviors?

What are the new findings?

- Polygenic risk scores for both type 2 diabetes and physical activity-related phenotypes
independently predict the incidence of type 2 diabetes and its comorbidities.

- Incorporating physical activity-related polygenic risk scores into the model does not
significantly improve predictive accuracy beyond the type 2 diabetes risk score alone.

- The findings support the hypothesis that genetic pleiotropy may partially explain
associations between type 2 diabetes and physical activity behavior.

How might this impact on clinical practice in the foreseeable future?

• 　Although polygenic risk scores for type 2 diabetes may aid in identifying high-risk
individuals for targeted prevention, their integration into clinical practice requires
further validation.
81

INTRODUCTION

Diabetes is one of the fastest growing diseases worldwide and is projected to affect 783 million adults by 2045 [1]. This rise is largely driven by 2 diabetes, which accounts for 80–90% of all diabetes cases [2]. Type 2 diabetes and its comorbidities, including cardiovascular disease, stroke, kidney failure, and lower limb amputation, cause considerable human suffering and place a heavy burden on healthcare systems worldwide [1–3]. Globally, the main drivers of this trend are an aging population, sedentary lifestyles, and unhealthy lifestyles associated with obesity [1]. Identifying individuals at high risk of developing type 2 diabetes is thus a key component of population-level prevention strategies.

The etiology of type 2 diabetes is multifaceted, involving complex interactions between genetics, environment, and lifestyle, with effects accumulating over the life course [4]. Twin models suggest that genetics accounts for a considerable amount (30–70%) of the variation in disease risk [5,6]. Recent advancements in genetics and large genome-wide association studies (GWASs) have identified many common genetic variants that increase type 2 diabetes risk [7–9]. These findings have enabled the development of polygenic risk scores (PRSs), which estimate an individual's genetic liability for different diseases [10]. PRSs are regarded as useful tools for predicting genetic susceptibility to complex traits [11], and for type 2 diabetes, they have been validated across populations [12,13]. They also show promise as screening tools for identifying individuals at elevated risk [13], potentially enabling more targeted preventive lifestyle interventions. In addition to identifying disease risk, genetic information may help predict the risk of type 2 diabetes comorbidities and treatment responses, including the likely effects of drug and lifestyle interventions. Because genetic risk estimates can be calculated at the time of birth, they may provide an early marker for identifying individuals at high risk of developing type 2 diabetes.

Despite this promise, the clinical use of PRSs has been limited. Current scores explain only part of the genetic variance and improve risk prediction only marginally compared with standard clinical risk factors [14,15]. Previous studies have shown that combining multiple PRS may improve predictive accuracy for type 2 diabetes and other diseases compared to using a single PRS alone [16,17]. Importantly, type 2 diabetes is fundamentally a multifactorial disease, and modifiable lifestyle factors (e.g., physical activity and obesity) are key drivers of disease development and progression [18,19]. Genetic variants related to physical activity

behavior—such as sedentary behavior (SB) [20]—and traits reflecting physical performance, including grip strength [21,22], cardiorespiratory fitness (CRF) [23], and body mass index (BMI) [24], have been associated with type 2 diabetes and other cardiometabolic diseases [25,26]. These findings suggest that physical activity-related traits are closely intertwined with type 2 diabetes and may further improve genetic prediction.

In light of evidence suggesting potential genetic pleiotropy between type 2 diabetes traits and physical activity behavior [25–27], we propose an expanded approach to genetic prediction. Specifically, we examine whether higher genetic liability for type 2 diabetes is associated with an increased risk of type 2 diabetes and its comorbidities at the population level and whether prediction improves when incorporating physical activity-related genetic liabilities into the model. We hypothesize that including physical activity-related PRSs in addition to the type 2 diabetes PRS will improve the accuracy of predicting type 2 diabetes and its comorbidities.

METHODS

Study cohorts

This retrospective cohort study was conducted using FinnGen as the main cohort. It is a public–private partnership research project launched in 2017 that links genotype and digital health record data from Finnish health registries using unique national personal identification numbers (https://www.finngen.fi/en) [28]. We used the FinnGen data release 12 (R12), which includes 520,210 biobank participants (10% of the Finnish population). A complete case approach was applied, requiring participants to have all necessary information for each endpoint analysis. This resulted in a smaller sample size (n = 279,373) compared to the R12.

Genotyping, quality control, and imputation

The FinnGen individuals were genotyped using Illumina and Affymetrix chip arrays (Illumina Inc., San Diego, and Thermo Fisher Scientific, Santa Clara, CA, USA). Detailed information on genotyping, quality control, and imputation is available in the FinnGen documentation (https://finngen.gitbook.io/documentation/) [28].

Polygenic risk scoring

Based on a literature search, we selected the publicly available genome-wide association study (GWAS) summary statistics previously published by Mahajan et al. [29] as *the base data* for

type 2 diabetes PRS calculation. We selected the most comprehensive publicly available dataset with individuals of European ancestry, as it has been suggested that type 2 diabetes differs in genetic factors and pathophysiology based on ethnicity [30]. The base data included 898,130 genotyped individuals (74,124 type 2 diabetes cases and 824,006 controls) from 32 European ancestry cohorts.

Analysis included several novel, physical activity-related PRSs: physical activity (PA), sedentary behavior (SB), muscular strength (grip), cardiorespiratory fitness (CRF), and body mass index (BMI). All PRSs were based on publicly available GWAS summary statistics from Pan-UK Biobank [32]. With the exception of PA, these PRSs have been previously validated [21,23,33,34]. The PA PRS was validated in this study, with details provided in the Supplemental Material.

Individual genetic scores were calculated using SBayesR, a Bayesian multiple regression approach based on genome-wide summary statistics [35]. SbayesR re-weights summary statistics to account for the linkage disequilibrium between each variant while restricting analyses to HapMap3 SNPs for computational efficiency. All PRSs were genome-wide scores, limited to over 1 million SNPs for computational purposes. The pipeline and code are available elsewhere [21].

Outcomes
The selection of type 2 diabetes comorbidities was based on the conditions causing the highest healthcare costs in Finland [36–38] and were defined using FinnGen endpoint definitions. Selected outcomes and their ICD-10 codes were type 2 diabetes (E11), hard cardiovascular diseases (hereafter severe cardiovascular diseases [CVD]; I20, I21, I22, I23, I24, I25, I61, I63, I64), diabetic nephropathy (N08.3), diabetic neuropathy (E11.4, G63.2), and diabetic retinopathy (H36.00, H36.02, H36.03). The selected endpoints and their FinnGen Labels are provided in the Supplemental Material. Register data were derived from national hospital discharge records available since 1968. Additional descriptive information, such as disease prevalence and age distribution, can be queried using FinnGen labels via the Risteys interface (https://risteys.finngen.fi/).

Covariates

Covariates were selected based on prior literature, but their availability in FinnGen was limited. Variables with the most comprehensive data were prioritized. Individual analyses included the first 10 principal components of ancestry, sex, BMI, and smoking status (self-reported yes or no) [39], and genotyping batch, which accounts for the potential stratification that may occur from the genotyping array and sample. Phenotype data were obtained from the Finnish biobanks (https://www.finngen.fi/en/data_protection/data-protection-statement).

Statistical analysis

Cox proportional hazards models were used to assess associations between PRSs and selected endpoints in the FinnGen cohort. Proportional hazard assumptions were evaluated using Schoenfeld residuals. Potential sex interactions for each PRS were investigated for the type 2 diabetes endpoint, and significant interactions were observed for sex × type 2 diabetes PRS (p = 6.9e-04), sex × SB PRS (p = 3.0e-04), and sex × BMI PRS (p = 2.6e-04). However, the hazard ratios were statistically significant and directionally consistent in both men and women (see Supplemental Material), so analyses were not disaggregated by sex.

Follow-up began at birth for type 2 diabetes outcomes, as PRSs are stable from conception. For comorbidity outcomes, follow-up began at type 2 diabetes diagnosis, ensuring that individuals were only at risk for comorbidities after disease onset and avoiding disease-free survival time before diagnosis, during which the outcome could not have occurred [40]. Follow-up ended at the first occurrence of the endpoint of interest or the end of follow-up, whichever occurred first.

Each PRS was first analyzed individually using Cox regression models. Subsequently, each of the five additional PRSs was added separately to a model to assess incremental predictive value. Finally, all six PRSs were included simultaneously in a multivariable model to evaluate whether combining multiple PRSs improves the prediction beyond type 2 diabetes PRS alone. With > 200 cases per endpoint, sufficient statistical power was expected, using the classical definition of 10 cases per predictor variable.

The concordance index (C-index) was used to evaluate the discriminative ability and performance of the predictive models. The C-index is a measure of a model's ability to distinguish between individuals who will develop the disease and those who will not [41]. A

C-index value of 0.5 indicates no better than random prediction, while a value of 1.0 indicates
perfect discrimination.

Standardized PRSs were used in all models; hence, the hazard ratio indicates the risk of
incidence per one standard deviation (SD) unit change in the PRS. The significance threshold
was set to $p < 0.05$, with no adjustment for multiple testing. All analyses were performed using
R (version 4.4.1, R Foundation for Statistical Computing, Vienna, Austria). We used the R
survival package [42] to estimate hazard ratios (HRs) and 95% confidence intervals (CIs)
between PRSs and incident type 2 diabetes and its comorbidities in the FinnGen cohort.

RESULTS

Table 1 shows the main characteristics of the FinnGen participants. A slight majority (52.2%)
were women, and the mean age at the end of follow-up was 62.0 years (range: 3.5–107.5).
Participants' BMI was 27.4 ± 5.4, and most (73.9%) were non-smokers.

Associations between PRSs and incident type 2 diabetes
One SD increase in type 2 diabetes PRS was associated with an 8% higher risk of incident type
2 diabetes (HR 1.08, [95% CI 1.08–1.08]; Table 2). All physical activity-related PRSs were
associated with type 2 diabetes risk. Lower risk was observed for PA 7% (HR 0.93, [95% CI
0.92–0.93]), grip 4% (HR 0.96, [95% CI 0.95–0.96]), and CRF 6% (HR 0.94, [95% CI 0.94–
0.95]). Higher risk was observed for SB 14% (HR 1.14, [95% CI 1.13–1.15]) and BMI 35%
(HR 1.35, [95% CI 1.34–1.36]). However, these associations were slightly attenuated when the
models were adjusted for measured BMI and smoking status (Table 2).

Associations between PRSs and incident type 2 diabetes comorbidities
Diabetic nephropathy. One SD increase in type 2 diabetes PRS was associated with a 4%
higher risk of diabetic nephropathy (HR 1.04, [95% CI 1.02–1.06]; Table 3). PA and CRF
PRSs were associated with a lower risk of nephropathy, while SB and BMI PRSs were linked
to a higher risk.

Diabetic retinopathy. Type 2 diabetes PRS was associated with a 4% higher risk of diabetic
retinopathy (HR 1.04, [95% CI 1.03 to 1.06]; Table 3). PA PRS predicted a lower risk of
retinopathy, while SB and BMI PRSs predicted a higher risk.

Diabetic neuropathy. The type 2 diabetes PRS was not significantly associated with diabetic
neuropathy. SB and BMI PRSs predicted higher risk, while grip PRS was also linked to an
increased risk of neuropathy.

Severe CVD. Type 2 diabetes PRS was associated with a 5% higher risk of severe CVD (HR
1.05 [95% CI 1.03 to 1.06]). PA, grip, and CRF PRSs were linked to a modestly reduced risk
of CVD (1–3%), whereas SB and BMI PRSs were associated with a higher risk of CVD. After
adjusting the model for measured BMI and smoking status, PA PRS was no longer statistically
significant.

Prediction of type 2 diabetes and comorbidities with PRSs
Model performance was also evaluated using the concordance index. In the base model, which
incorporated only the type 2 diabetes PRS for risk prediction, the C-index was 0.644. Adding
other PRSs had little effect, with a maximum increase of 0.028, and the HR for type 2 diabetes
PRS remained largely unchanged. In contrast, adding measured BMI and smoking status
increased the C-index for type 2 diabetes by 0.1, but not for comorbidities (Table 4).

DISCUSSION

The aim of this study was to assess how genetic factors, including those related to physical
activity, contribute to the risk of developing type 2 diabetes and its comorbidities in the Finnish
population. We found that higher genetic liability to type 2 diabetes was associated with a
greater risk of developing the disease, consistent with previous studies [12,43]. Among
individuals with type 2 diabetes, type 2 diabetes PRS was associated with a higher risk of
nephropathy, retinopathy, and severe CVDs, but not with neuropathy. Several physical
activity-related PRSs were independently associated with type 2 diabetes and its comorbidities,
but their inclusion in the model did not significantly improve prediction, suggesting potential
genetic pleiotropy.

To the best of our knowledge, this is the first study to examine whether physical activity-related
polygenic scores can improve the prediction of type 2 diabetes. While previous research has
examined interactions between lifestyle and genetic risk, no studies have directly combined
physical activity-related PRSs with type 2 diabetes PRS in a single predictive framework.
Although adding physical activity-related PRSs did not improve predictive accuracy in our
study, this approach provides a novel perspective. It may support the hypothesis that shared
genetic factors influence both type 2 diabetes susceptibility and physical activity behavior. This
aligns with earlier findings suggesting that physical activity is heritable and genetically
correlated with several cardiometabolic traits, including type 2 diabetes [25,44]. Grip
strength—a proxy for muscle strength—has been associated with improved metabolic health
and reduced type 2 diabetes risk, likely through mechanisms involving greater muscle mass
and enhanced insulin sensitivity [21,22]. Likewise, genetic predisposition to sedentary
behavior is correlated with increased type 2 diabetes risk, supporting the role of prolonged
inactivity in disease development [45]. Similarly, BMI is a well-established risk factor, with
higher BMI consistently associated with an increased risk of type 2 diabetes [24].

The limited improvement in prediction, as indicated by the C-index, could be due to
overlapping genetic signals between PRSs, their low individual explanatory power, and the
complex polygenic architecture of type 2 diabetes and related traits [29,46]. Nevertheless,
methodological advances may improve the integration of polygenic scores in the future.
Notably, predictive performance improved more clearly when measured lifestyle-related
phenotypic variables, such as smoking and BMI, were added to the model (C-index increased
from 0.644 to 0.744), compared to the addition of physical activity-related PRSs. This suggests
that direct measures of lifestyle factors currently add more predictive value than their polygenic
proxies, although methodological development may narrow this gap.

Although the observed effect sizes were modest, our findings support the potential role of PRSs
in preventive strategies for type 2 diabetes. Even modest gains in risk stratification may have
clinical significance, especially in terms of early intervention and targeted prevention.
Currently, the clinical use of PRSs is largely confined to research and pilot programs, but their
potential for disease prevention is increasingly recognized. Traditional risk assessment tools
remain essential for population-level screening, yet our findings suggest that PRSs could
provide an additional, genetically informed layer of risk evaluation. Recent studies also

indicate that PRS-based screening may be cost-effective when focused on high-risk individuals

and combined with affordable genotyping technologies [47]. Importantly, observational data

show that individuals with high polygenic risk still benefit significantly from healthy lifestyle

choices, underscoring the value of early risk identification [48]. Thus, while PRS-based

prevention is not yet part of standard care, it may hold promise as a future tool for more

personalized and proactive disease prevention strategies.

Considering the inclusion of multiple validated PRSs in this study, it is noteworthy that while

all physical activity-related PRSs predicted T2D risk to some extent, their predictive

performance varied. These differences may partly reflect disparities in the underlying GWAS

data used to construct the scores. For instance, the PRS for cardiorespiratory fitness was

derived from a considerably smaller GWAS sample compared to those for sedentary behavior

or BMI, potentially limiting its predictive power due to reduced statistical power and variant

discovery. Sedentary behavior and BMI are well-established lifestyle-related risk factors for

type 2 diabetes, which may explain their stronger predictive performance. These traits are also

likely to have more robust and well-powered GWASs, resulting in more informative PRSs. We

found that the BMI PRS outperformed the type 2 diabetes PRS in predicting type 2 diabetes

and its comorbidities. This suggests that PRSs for intermediate traits, such as BMI, may

outperform disease-specific PRSs in predicting future disease onset. Our findings are consistent

with UK Biobank analyses showing that the BMI PRS predicted type 2 diabetes incidence more

accurately than the type 2 diabetes PRS, particularly in women [49]. Recent research further

supports the utility of PRSs in identifying individuals at elevated genetic risk before the onset

of clinical symptoms [50]. Based on the current evidence, PRSs reflecting modifiable risk

pathways may capture important biological mechanisms underlying disease development and

offer greater utility for screening.

Strengths and limitations

This study has several strengths. We applied high-performing, genome-wide methods for

genetic scoring. Specifically, we used the SBayesR method to derive type 2 diabetes PRS,

which has been shown to outperform other commonly utilized PRS methods. A key strength is

the use of GWAS data from Mahajan et al. (2018) [29], which provide the best predictive

performance for type 2 diabetes PRSs when combined with advanced Bayesian methods such

as SBayesR [31]. Another strength is the inclusion of multiple validated PRSs, including the

most up-to-date and best-performing scores for physical activity-related traits, thereby

enhancing the robustness of genetic risk assessment. Furthermore, we leveraged the large-scale FinnGen cohort, which covers approximately 10% of the Finnish adult population, and linked genetic data to comprehensive national health registers. This enabled detailed and reliable phenotyping with near-complete follow-up, which strengthens the reliability of our findings. To the best of our knowledge, FinnGen has not been widely used in previous studies of type 2 diabetes PRSs, making this study a valuable addition to the literature by validating findings in an independent, population-based dataset and broadening the generalizability of PRS research beyond commonly used cohorts.

However, the generalizability of our findings is limited to European populations, as both the underlying GWAS data and the FinnGen cohort are composed of individuals of European descent. Our analyses were also constrained by the lack of detailed covariate data, particularly on lifestyle factors such as diet, physical activity, and socioeconomic status. Nonetheless, the primary aim of this study was to evaluate the independent predictive utility of type 2 diabetes PRSs in early-stage screening, rather than to test their performance when adjusted for lifestyle-related variables. Additionally, FinnGen may overrepresent individuals with a higher disease burden, as participants are primarily recruited from those with healthcare contact, which could influence the generalizability of lifetime risk estimates.

Conclusions

PRSs for type 2 diabetes and physical activity-related phenotypes independently predict the incidence of type 2 diabetes and related comorbidities. However, adding physical activity-related scores to the model did not meaningfully improve prediction. These findings support the hypothesis that genetic pleiotropy may partly explain associations between type 2 diabetes and physical activity behavior.

Acknowledgements

We thank the participants and all those who contributed to the data collection in the FTC and FinnGen cohorts, without whom this study would not have been possible. A detailed list of investigators involved in FinnGen is provided in the Supplemental Material (pages 2–17).

We used AI-assisted tools (DeepL and ChatGPT) for language editing, proofreading, and improving the clarity and structure of the manuscript. All content was reviewed and verified by the authors.

Sources of Funding

This work was funded by Research Council of Finland (grants 341750, 346509, and 361981),

Juho Vainio Foundation, Päivikki and Sakari Sohlberg Foundation, all to ES. The FinnGen

project is funded by Business Finland and 13 international pharmaceutical industry partners:

AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene/Bristol–Myers Scibb,

Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck,

Novartis, Pfizer, and Sanofi. The funders did not affect this study in any way.

Disclosures

Competing interests. The authors declare no competing interests.

Data availability. Data are available upon reasonable request. Researchers can apply to use

the FinnGen resource and access the data used. The Finnish biobank data can be accessed

through the Fingenious services (https://site.fingenious.fi/en/) managed by FINBB (Finnish

Biobank Cooperative – FINBB | Finnish Biobank Cooperative – FINBB). The FTC subsample

data are taken from the Biobank of the National Institute for Health and Welfare. Data are

available for qualified researchers through a standardized application procedure (see

details Data and services - THL).

Contributorship. EV, LJ, KW, and ES conceptualized the research question, study design,

and statistical analysis. EV and LJ preprocessed the polygenic score data and implemented the

scores to the FinnGen study cohort. EV performed the statistical modelling under the

supervision of LJ and ES. EV drafted the first version of the manuscript, and all authors

contributed significantly to the writing, critical interpretation of the findings, and revision of

the manuscript. The corresponding author attests that all listed authors meet authorship criteria

and that no others meeting the criteria have been omitted.

References

1. International Diabetes Federation; (2021); IDF Diabetes Atlas; Available from https://diabetesatlas.org; Accessed 26 July 2024.

2. International Diabetes Federation (2024) Available from: https://idf.org/about-diabetes/type-2-diabetes. Accessed 26 July 2024.

3. Ong KL, Stafford LK, McLaughlin SA, et al. (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2023 Jul 15;402(10397):203–34. doi: 10.1016/S0140-6736(23)01301-6.

4. Cole JB, Florez JC. (2020) Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020 Jul;16(7):377–90. doi: 10.1038/s41581-020-0278-5.

5. Almgren P, Lehtovirta M, Isomaa B, et al. (2011) Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. Diabetologia. 2011 Nov 1;54(11):2811–9. doi: 10.1007/s00125-011-2267-5.

6. Willemsen G, Ward KJ, Bell CG, et al. (2015) The concordance and heritability of type 2 diabetes in 34,166 twin pairs from international twin registers: the Discordant Twin (DISCOTWIN) Consortium. Twin Res Hum Genet Off J Int Soc Twin Stud. 2015 Dec;18(6):762–71. doi: 10.1017/thg.2015.83.

7. Pärna K, Snieder H, Läll K, Fischer K, Nolte I. (2020) Validating the doubly weighted genetic risk score for the prediction of type 2 diabetes in the Lifelines and Estonian Biobank cohorts. Genet Epidemiol. 2020 Sep;44(6):589–600. doi: 10.1002/gepi.22327.

8. Scott LJ, Mohlke KL, Bonnycastle LL, et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007 Jun 1;316(5829):1341–5. doi: 10.1126/science.1142382.

9. Visscher PM, Wray NR, Zhang Q, et al. (2017) 10 Years of GWAS Discovery: biology, function, and translation. Am J Hum Genet. 2017 Jul 6;101(1):5–22. doi: 10.1016/j.ajhg.2017.06.005.

10. Wand H, Lambert SA, Tamburro C, et al. (2021) Improving reporting standards for polygenic scores in risk prediction studies. Nature. 2021 Mar;591(7849):211–9. doi: 10.1038/s41586-021-03243-6.

11. Boyle EA, Li YI, Pritchard JK. (2017) An expanded view of complex traits: from polygenic to omnigenic. Cell. 2017 Jun 15;169(7):1177–86. doi: 10.1016/j.cell.2017.05.038.

12. Ge T, Irvin MR, Patki A, et al. (2022) Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations. Genome Med. 2022 Jun 29;14(1):70. doi: 10.1186/s13073-022-01074-2.

13. Liu W, Zhuang Z, Wang W, Huang T, Liu Z. (2021) An improved genome-wide polygenic score model for predicting the risk of type 2 diabetes. Front Genet. 2021 Feb 11;12:632385. doi: 10.3389/fgene.2021.632385.

14. DeForest N, Majithia AR. (2022) Genetics of type 2 diabetes: implications from large-scale studies. Curr Diab Rep. 2022 May 1;22(5):227–35. doi: 10.1007/s11892-022-01462-3.

15. Koch S, Schmidtke J, Krawczak M, Caliebe A. (2023) Clinical utility of polygenic risk scores: a critical 2023 appraisal. J Community Genet. 2023 Oct 1;14(5):471–87. doi: 10.1007/s12687-023-00645-z.

16. Albiñana C, Zhu Z, Schork AJ, et al. (2023) Multi-PGS enhances polygenic prediction by combining 937 polygenic scores. Nat Commun. 2023 Aug 5;14(1):4702. doi: 10.1038/s41467-023-40330-w.

17. Klau JH, Maj C, Klinkhammer H, et al. (2023) AI-based multi-PRS models outperform classical single-PRS models. Front Genet. 2023 Jun 27;14. doi: 10.3389/fgene.2023.1217860.

18. Borné Y, Nilsson PM, Melander O, Hedblad B, Engström G. (2015) Multiple anthropometric measures in relation to incidence of diabetes: a Swedish population-based cohort study. Eur J Public Health. 2015 Dec 1;25(6):1100–5. doi: 10.1093/eurpub/ckv044.

19. Yang W, Wu Y, Chen Y, et al. (2024) Different levels of physical activity and risk of developing type 2 diabetes among adults with prediabetes: a population-based cohort study. Nutr J. 2024 Sep 17;23(1):107. doi: 10.1186/s12937-024-01013-4.

20. Wang Z, Emmerich A, Pillon NJ, et al. (2022) Genome-wide association analyses of physical activity and sedentary behavior provide insights into underlying mechanisms and roles in disease prevention. Nat Genet. 2022 Sep;54(9):1332–44. doi: 10.1038/s41588-022-01165-1.

21. Herranen P, Palviainen T, Rantanen T, et al. (2022) A polygenic risk score for hand grip strength predicts muscle strength and proximal and distal functional outcomes among older women. Med Sci Sports Exerc. 2022 Nov;54(11):1889. doi: 10.1249/MSS.0000000000002981.

22. Boonpor J, Parra-Soto S, Petermann-Rocha F, et al. (2021) Associations between grip strength and incident type 2 diabetes: findings from the UK Biobank prospective cohort study. BMJ Open Diabetes Res Care. 2021 Aug 5;9(1):e001865. doi: 10.1136/bmjdrc-2020-001865.

23. Joensuu L, Lukander V, Herranen P, et al. (2025) Genetic contribution of cardiorespiratory fitness in morbidity and mortality: a prospective FinnGen and HUNT study. medRxiv p. 2025.06.25.25330268. Available from: https://www.medrxiv.org/content/10.1101/2025.06.25.25330268v1. Accessed 21 August 2025.

24. Zhang M, Ward J, Strawbridge RJ, et al. (2025) Genetic predisposition to adiposity, and type 2 diabetes: the role of lifestyle and phenotypic adiposity. Eur J Endocrinol. 2025 May 2;192(5):549–57. doi: 10.1093/ejendo/lvaf084.

25. Sillanpää E, Palviainen T, Ripatti S, Kujala UM, Kaprio J. (2022) Polygenic score for
physical activity is associated with multiple common diseases. Med Sci Sports Exerc.
2022 Feb 1;54(2):280–7. doi: 10.1249/MSS.0000000000002788.

26. Tynkkynen NP, Törmäkangas T, Palviainen T, et al. (2023) Associations of polygenic
inheritance of physical activity with aerobic fitness, cardiometabolic risk factors and
diseases: the HUNT study. Eur J Epidemiol. 2023 Sep 1;38(9):995–1008. doi:
10.1007/s10654-023-01029-w.

27. Herranen P, Koivunen K, Palviainen T, et al. (2024) Genome-wide polygenic score for
muscle strength predicts risk for common diseases and lifespan: a prospective cohort
Study. J Gerontol Ser A. 2024 Apr 1;79(4):glae064. doi: 10.1093/gerona/glae064.

28. Kurki MI, Karjalainen J, Palta P, et al. (2023) FinnGen provides genetic insights from a
well-phenotyped isolated population. Nature. 2023 Jan;613(7944):508–18. doi:
10.1038/s41586-022-05473-8.

29. Mahajan A, Taliun D, Thurner M, et al. (2018) Fine-mapping type 2 diabetes loci to
single-variant resolution using high-density imputation and islet-specific epigenome
maps. Nat Genet. 2018 Nov;50(11):1505–13. doi: 10.1038/s41588-018-0241-6.

30. Polfus LM, Darst BF, Highland H, et al. (2021) Genetic discovery and risk
characterization in type 2 diabetes across diverse populations. Hum Genet Genomics
Adv. 2021 Mar 9;2(2):100029. doi: 10.1016/j.xhgg.2021.100029.

31. Brīvība M, Atava I, Pečulis R, et al. (2024) Evaluating the efficacy of Type 2 diabetes
polygenic risk scores in an independent European population. Int J Mol Sci. 2024
Jan;25(2):1151. doi: 10.3390/ijms25021151.

32. Pan-UK Biobank (2025) Available from: https://pan.ukbb.broadinstitute.org. Accessed
25 August 2025.

33. Joensuu L, Koivunen K, Tynkkynen NP, et al. (2025) Genetic liability to sedentary
behaviour and cardiovascular disease incidence in the FinnGen and HUNT cohorts. Br J
Sports Med 2025 May 27;59(11):783-790. doi: 10.1136/bjsports-2024-109491.

34. Masip G, Silventoinen K, Keski-Rahkonen A, et al. (2020) The genetic architecture of
the association between eating behaviors and obesity: combining genetic twin modeling
and polygenic risk scores. Am J Clin Nutr. 2020 Jul 20;112(4):956–66. doi:
10.1093/ajcn/nqaa181.

35. Lloyd-Jones LR, Zeng J, Sidorenko J, et al. (2019) Improved polygenic prediction by
Bayesian multiple regression on summary statistics. Nat Commun. 2019 Nov
8;10(1):5086. doi: 10.1038/s41467-019-12653-0.

36. Einarson TR, Acs A, Ludwig C, Panton UH. (2018) Economic burden of cardiovascular
disease in Type 2 diabetes: a systematic review. Value Health. 2018 Jul 1;21(7):881–90.
doi: 10.1016/j.jval.2017.12.019.

37. Kurkela O, Raitanen J, Tuovinen M, Ilanne-Parikka P, Forma L. (2022) Tyypin 2
diabeteksen lisäsairaudet aiheuttavat merkittävän kustannustaakan. Suom Lääkäril
2022;77:e32697.38.

38. Niskanen L, Partonen T, Auvinen A, Haukka J. Trends and predictors in all-cause and
cause-specific mortality in diabetic and reference populations during 21 years of follow-
up. J Epidemiol Community Health. 2020 Nov 1;74(11):950–6. doi: 10.1136/jech-2019-
213602.

39. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. (2006)
Principal components analysis corrects for stratification in genome-wide association
studies. Nat Genet. 2006 Aug;38(8):904–9. doi: 10.1038/ng1847.

40. Kolde A, Koitmäe M, Käärik M, Möls M, Fischer K. (2025) Analysis of follow-up data
in large biobank cohorts: a review of methodology. Front Genet 2025 Jun
25:16:1534726. doi: 10.3389/fgene.2025.1534726.

41. Gerds TA, Kattan MW, Schumacher M, Yu C. (2013) Estimating a time-dependent
concordance index for survival prediction models with covariate dependent censoring.
Stat Med. 2013 Jun 15;32(13):2173–84. doi: 10.1002/sim.5681.

42. Therneau T. (2025) Survival: Survival Analysis. Version 3.5-8. Available from
https://cran.r-project.org/web/packages/survival/index.html. Accessed 12 March 2025.

43. Yun JS, Jung SH, Shivakumar M, et al. (2022) Polygenic risk for type 2 diabetes,
lifestyle, metabolic health, and cardiovascular disease: a prospective UK Biobank study.
Cardiovasc Diabetol. 2022 Jul 14;21(1):131. doi: 10.1186/s12933-022-01560-2.

44. Kujala UM, Palviainen T, Pesonen P, et al. (2020) Polygenic risk scores and physical
activity. Med Sci Sports Exerc. 2020 Jul;52(7):1518–24. doi:
10.1249/MSS.0000000000002290.

45. Hamilton MT, Hamilton DG, Zderic TW. (2014) Sedentary behavior as a mediator of
type 2 diabetes. Med Sport Sci. 2014;60:11–26. doi: 10.1159/000357332

46. Torkamani A, Wineinger NE, Topol EJ. (2018) The personal and clinical utility of
polygenic risk scores. Nat Rev Genet. 2018 Sep;19(9):581–90. doi: 10.1038/s41576-018-
0018-x.

47. Martikainen J, Lehtimäki AV, Jalkanen K, et al. (2022) Economic evaluation of using
polygenic risk score to guide risk screening and interventions for the prevention of type 2
diabetes in individuals with high overall baseline risk. Front Genet. 2022 Sep
15;13:880799. doi: 10.3389/fgene.2022.880799.

48. Lankinen MA, Nuotio P, Kauppinen S, et al. (2024) Effects of genetic risk on incident
type 2 diabetes and glycemia: the T2D-GENE Lifestyle Intervention Trial. J Clin
Endocrinol Metab. 2024 Jun 18;110(1):130–8. doi: 10.1210/clinem/dgae422.

49. Moldovan A, Waldman YY, Brandes N, Linial M. (2021) Body mass index and birth
weight improve polygenic risk score for type 2 diabetes. J Pers Med. 2021 Jun
21;11(6):582. doi: 10.3390/jpm11060582.

50. German C, Ashenhurst J, Wang W, et al. (2023) A polygenic risk score identifies
undiagnosed cases of diabetes. medRxiv 10.31.23297847 (Preprint). Available from:
https://www.medrxiv.org/content/10.1101/2023.10.31.23297847v1. Accessed 18 June
2025.

Tables

Table 1. Descriptives of individuals with selected endpoints in the main FinnGen cohort

Characteristics	All	n	Women	n	Men	n
age (y)	62.0 (17.2)	279,373	59.1 (17.6)	145,794	65.2 (16.2)	133,579
BMI (kg/m^2)	27.4 (5.4)	279,373	27.3 (5.9)	145,794	27.4 (4.7)	133,579
Smoker *n* (%)	73.011 (26.1)	279,373	26.612 (18.3)	145,794	46.399 (34.7)	133,579
Comorbidities						
T2D	50.248 (18.0)	279,373	20.890 (14.3)	145,794	29.358 (22.0)	133,579
CVD severe	10.073 (23.9)	42,225	15.018 (10.3)	145,794	35.812 (26.8)	133,579
Diabetic neuropathy	1.669 (3.4)	49,652	589 (2.8)	20,798	1.410 (4.8)	29,354
Diabetic nephropathy	2.345 (4.7)	49,560	861 (4.1)	20,813	1945 (6.6)	29,377
Diabetic retinopathy	2.115 (4.6)	45,558	984 (5.1)	19,182	1.536 (5.7)	26,945

Notes: Values are means and standard deviations (SD) for continuous variables, and n and percentages (%) are given for others; BMI, body mass index; T2D, type 2 diabetes; CVD, cardiovascular disease; age at the end of follow-up.

Table 2. Associations between PRSs and T2D incidence

T2D	Model 1[a]		Model 2[b]	
	HR (95% CI)	p Value	HR (95% CI)	p Value
PRS				
T2D	1.08 (1.08–1.08)	**0.0e+00**	1.07 (1.07–1.08)	**0.0e+00**
PA	0.93 (0.92–0.93)	**1.2e-67**	0.95 (0.94–0.96)	**4.4e-30**
SB	1.14 (1.13–1.15)	**4.4e-197**	1.09 (1.08–1.10)	**4.7e-78**
Grip	0.96 (0.95–0.96)	**5.7e-24**	0.96 (0.95–0.96)	**2.6e-24**
CRF	0.94 (0.94–0.95)	1.3e-36	0.96 (0.96–0.97)	7.2e-16
BMI	1.35 (1.34–1.36)	**0.0e+00**	1.13 (1.12–1.14)	**2.5e-144**
T2D + PA	1.08 (1.08–1.08)	**0.0e+00**	1.07 (1.07–1.08)	**0.0e+00**
T2D + SB	1.08 (1.07–1.08)	**0.0e+00**	1.07 (1.07–1.08)	**0.0e+00**
T2D + Grip	1.08 (1.08–1.08)	**0.0e+00**	1.07 (1.07–1.08)	**0.0e+00**
T2D + CRF	1.08 (1.08–1.08)	**0.0e+00**	1.07 (1.07–1.08)	**0.0e+00**
T2D + BMI	1.07 (1.07–1.08)	**0.0e+00**	1.07 (1.07–1.08)	**0.0e+00**
All PRSs	1.07 (1.07–1.08)	**1.5e-320**	1.07 (1.07–1.08)	**0.0e+00**

a. Model 1 adjusted for sex, age, 10 genetic principal components, and genotyping batch.
b. Model 2 adjusted for sex, age, 10 genetic principal components, genotyping batch, BMI, and smoking status.
PRSs: T2D, Type 2 diabetes; PA, physical activity; Grip, handgrip; CRF cardiorespiratory fitness; BMI, body mass index.

Table 3. Associations between PRSs and T2D comorbidities

Disease	PRS	Model 1[a]		Model 2[b]	
		HR (95% CI)	p Value	HR (95% CI)	p Value
Diabetic nephropathy	T2D	1.04 (1.02–1.06)	**4.3e-06**	1.04 (1.03–1.06)	**2.2e-06**
	PA	0.93 (0.89–0.97)	**4.3e-04**	0.94 (0.90–0.98)	**2.33-03**
	SB	1.09 (1.05–1.14)	**2.7e-05**	1.07 (1.02–1.11)	**1.93-03**
	Grip	1.00 (0.96–1.04)	8.8e-01	1.00 (0.96–1.04)	0.990
	CRF	0.95 (0.91–0.99)	**1.4e-02**	0.96 (0.92–0.96)	**0.032**
	BMI	1.32 (1.26–1.37)	**2.1e-39**	1.24 (1.18–1.28)	**2.7e-21**

		Model 1[a]		Model 2[b]	
	T2D + PA	1.04 (1.02–1.06)	**8.3e-06**	1.04 (1.02–1.06)	**4.0e-06**
	T2D + SB	1.04 (1.02–1.06)	**9.4e-06**	1.04 (1.03–1.06)	**3.9e-06**
	T2D + Grip	1.04 (1.02–1.06)	**4.3e-06**	1.04 (1.03–1.06)	**2.2e-06**
	T2D + CRF	1.04 (1.02–1.06)	**4.9e-06**	1.04 (1.03–1.06)	**2.4e-06**
	T2D + BMI	1.03 (1.01–1.05)	**1.7e-03**	1.04 (1.02–1.06)	**2.3e-04**
	All	1.03 (1.01–1.05)	**1.8e-03**	1.04 (1.02–1.06)	**2.5e-04**
Diabetic neuropathy	T2D	1.03 (1.00–1.06)	6.9e-02	1.03 (1.00–1.06)	0.061
	PA	0.98 (0.93–1.03)	3.3e-01	0.98 (0.94–1.03)	0.460
	CRF	1.01 (0.96–1.06)	8.2e-01	1.01 (0.96–1.06)	0.690
	SB	1.06 (1.01–1.11)	**2.1e-02**	1.05 (1.00–1.10)	0.076
	Grip	1.07 (1.02–1.12)	**5.9e-03**	1.07 (1.02–1.12)	**5.3e-03**
	CRF	1.01 (0.96–1.06)	8.2e-01	1.01 (0.96–1.06)	0.690
	BMI	1.16 (1.10–1.21)	**6.0e-09**	1.11 (1.06–1.17)	**3.8e-05**
	T2D + PA	1.01 (1.00–1.06)	7.5e-02	1.03 (1.00–1.06)	0.065
	T2D + SB	1.03 (1.00–1.06)	8.6e-02	1.03 (1.00–1.06)	0.072
	T2D + Grip	1.03 (1.00–1.06)	6.3e-02	1.03 (1.00–1.06)	0.056
	T2D + CRF	1.01 (1.00–1.06)	6.9e-02	1.03 (1.00–1.06)	0.060
	T2D + BMI	1.02 (0.99–1.05)	2.5e-01	1.02 (1.00–1.06)	0.160
	All	1.02 (0.99–1.05)	2.4e-01	1.02 (0.99–1.05)	0.160
Diabetic retinopathy	T2D	1.04 (1.03–1.06)	**1.0e-06**	1.04 (1.03–1.06)	**9.7e-07**
	PA	0.94 (0.90–0.98)	**3.8e-03**	0.94 (0.90–0.98)	**4.9e-03**
	SB	1.08 (1.03–1.12)	**7.2e-04**	1.07 (1.03–1.12)	**1.2e-03**
	Grip	0.96 (0.92–1.01)	8.0e-02	0.96 (0.92–1.01)	0.081
	CRF	0.97 (0.93–1.01)	1.2e-01	0.97 (0.93–1.01)	0.140
	BMI	1.25 (1.19–1.30)	**2.1e-23**	1.24 (1.19–1.30)	**2.3e-21**
	T2D + PA	1.04 (1.03–1.06)	**2.1e-06**	1.04 (1.03–1.06)	**2.0e-06**
	T2D + SB	1.04 (1.03–1.06)	**2.1e-06**	1.04 (1.03–1.06)	**1.9e-06**
	T2D + Grip	1.04 (1.03–1.06)	**1.4e-06**	1.04 (1.03–1.06)	**1.3e-06**
	T2D + CRF	1.04 (1.03–1.06)	**1.2e-06**	1.04 (1.03–1.06)	**1.2e-06**
	T2D + BMI	1.04 (1.02–1.06)	**2.3e-04**	1.04 (1.02–1.06)	**2.2e-04**
	All	1.04 (1.02–1.06)	**3.1e-04**	1.04 (1.02–1.06)	**2.9e-04**
Severe CVD	T2D	1.05 (1.03–1.06)	**1.1e-15**	1.05 (1.03–1.06)	**3.6e-16**
	PA	0.98 (0.96–1.00)	**2.0e-02**	0.98 (0.96–1.00)	0.0550
	SB	1.05 (1.03–1.08)	**1.4e-07**	1.04 (1.02–1.06)	**2.1e-05**
	Grip	0.97 (0.95–0.99)	**3.9e-03**	0.97 (0.95–0.99)	**3.5e-03**
	CRF	0.99 (0.97–1.01)	5.5e-01	1.00 (0.98–1.01)	0.670
	BMI	1.13 (1.11–1.16)	**6.7e-35**	1.11 (1.09–1.13)	**9.4e-23**
	T2D + PA	1.04 (1.03–1.06)	**2.3e-15**	1.05 (1.03–1.06)	**6.6e-16**
	T2D + SB	1.04 (1.03–1.06)	**4.7e-15**	1.04 (1.03–1.06)	**1.2e-15**
	T2D + Grip	1.04 (1.03–1.06)	**1.1e-15**	1.05 (1.03–1.06)	**3.5e-16**
	T2D + CRF	1.05 (1.03–1.06)	**1.2e-15**	1.05 (1.03–1.06)	**3.7e-16**
	T2D + BMI	1.04 (1.03–1.05)	**4.1e-11**	1.04 (1.03–1.05)	**2.9e-12**
	All	1.04 (1.03–1.05)	**4.4e-11**	1.04 (1.03–1.05)	**3.0e-12**

579   a. Model 1 adjusted for sex, 10 genetic principal components, and genotyping batch.
580   b. Model 2 adjusted for sex, 10 genetic principal components, genotyping batch, BMI, and smoking status.

593 **Table 4. PRSs as a Predictor of T2D in FinnGen**

Disease	C-index Model 1[a]	C-index Model 2[b]
T2D		
PRS		
T2D	0.644	0.744
PA	0.635	0.739
SB	0.641	0.74
Grip	0.634	0.739
CRF	0.634	0.739
BMI	0.665	0.741
T2D + PA	0.646	0.744
T2D + SB	0.65	0.745
T2D + Grip	0.645	0.744
T2D + CRF	0.645	0.744
T2D + BMI	0.671	0.745
All PRSs	0.672	0.746
Diabetic nephropathy		
PRS		
T2D	0.639	0.659
PA	0.638	0.658
SB	0.639	0.659
Grip	0.637	0.657
CRF	0.637	0.657
BMI	0.658	0.667
T2D + PA	0.64	0.66
T2D + SB	0.642	0.66
T2D + Grip	0.639	0.659
T2D + CRF	0.64	0.659
T2D + BMI	0.658	0.669
All PRSs	0.658	0.669
Diabetic neuropathy		
PRS		
T2D	0.656	0.664
PA	0.655	0.663
SB	0.656	0.664
Grip	0.656	0.664
CRF	0.655	0.663
BMI	0.661	0.667
T2D + PA	0.656	0.664
T2D + SB	0.657	0.665
T2D + Grip	0.657	0.665
T2D + CRF	0.656	0.664
T2D + BMI	0.662	0.667
All PRSs	0.663	0.668
Diabetic retinopathy		
PRS		
T2D	0.656	0.653
PA	0.653	0.65
SB	0.654	0.651
Grip	0.654	0.651
CRF	0.653	0.65
BMI	0.66	0.659
T2D + PA	0.656	0.653
T2D + SB	0.657	0.654

T2D + Grip	0.657	0.654
T2D + CRF	0.657	0.654
T2D + BMI	0.662	0.661
All PRSs	0.663	0.662
Severe CVD PRS		
T2D	0.645	0.651
PA	0.643	0.649
SB	0.644	0.649
Grip	0.643	0.649
CRF	0.643	0.648
BMI	0.649	0.652
T2D + PA	0.645	0.651
T2D + SB	0.646	0.651
T2D + Grip	0.645	0.651
T2D + CRF	0.645	0.65
T2D + BMI	0.651	0.654
All PRSs	0.651	0.654

594   a. Model 1 adjusted for sex, 10 genetic principal components, and genotyping batch.
595   b. Model 2 adjusted for sex, 10 genetic principal components, genotyping batch, BMI, and smoking status.